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immunostained with CD8 (C8/144B-Dako), FOXP3 (EP340-Epitomics),
PD-L1 (SP263-Ventana), and CD163 (EP324-Epitomics). CD8, FOXP3,
and CD163 expressions were separately evaluated in intratumoural(IT)
and stromal(S) areas. PD-L1 expression was also individually considered
in neoplastic cells (NC) and tumour-infiltrating-lymphocytes (TIL).
Results: All patients were female. Mean age was 52.7 (32-84) and mean
survival was 48.3 months (3.4-83.7). There was a significant positive corre-
lation between the expressions of each of the four antibodies (p<0.01).
Among the histological subtypes, higher expressions of CD8 (IT), FOXP3
(IT&S), PD-L1 (NC), and CD163 (IT&S) were found in lymphocyte-
predominant breast carcinomas (p<0.05). Expressions of CD8, FOXP3, and
CD163 (IT&S), and PD-L1 (TIL) were negatively related to angio and lym-
phatic invasion (p<0.01). Perineural invasion was more frequent in the cases
with lower CD8 (S) and FOXP3 (IT&S) and higher PD-L1 (TIL) expressions
(p<0.01). pT stage was reversely related to CD8 (S) and PD-L1 (TIL), how-
ever, it had a positive associationwith PD-L1 (NC) andCD163 (IT) (p<0.01).
Lower expressions of FOXP3 (IT&S), PD-L1 (TIL), and CD163 (IT) were
observed to be related with exitus (p<0.01). Local recurrence was negatively
associated with CD8 (S), FOXP3 (IT), PD-L1 (TIL), CD163 (S) (p<0.01).
Expressions of CD8 (S), FOXP3 (IT&S), PD-L1 (NC&TIL), and CD163
(IT&S) were lower in the cases with distant metastasis (p<0.01).
Conclusion: TIME is an important prognostic parameter and a potential
therapeutic marker. CD8, FOXP3, PD-L1, and CD163 antibodies are
useful to consider TIME and to predict prognosis in TNBC.
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Background & Objectives:Differences in the expression of biomarkers
in primary tumour tissue and metastases and the relationships of such
differences in breast cancer patients are not clear until now. Objective:
to reveal the relationship of estrogen receptor (ER) and Her2/neu changes
in locoregional metastases compared with primary tumour in the group of
breast cancer patients with equivocal Her2/neu expression level (2+).
Methods: 19 samples of primary tumour (Her2/neu expression 2+) and
corresponding metastases were stained immunohistochemically with
anti-ER (1D5, Dako) and anti-Her2/neu (4B5, Ventana) antibodies.
Primary tumour samples were additionally analysed using SISH technol-
ogy (Ventana). Staining results were evaluated using Allred score and
ASCO/CAP 2013 guideline. Frequencies of Her2/neu and ER expression
changes were compared using Fisher’s exact probability test.
Results: Her2/neu expression level was lower in metastases then in the
primary tumour in 16 cases (84,2%, 95% CI 59,5-95,8%) and higher – in
1 case out of 19 (5,3%, 95% CI 0,3-28,1%) (p<0,001). Her2/neu-statuses
of primary tumour and metastases were the same in 84,2% (95% CI 59,5-
95,8%) of cases. Among 16 cases with decreased Her2/neu expression
level in metastases we registered 9 cases with increase and 2 cases with
decrease of ER expression level (p=0,023).
Conclusion:We found simultaneous decrease of Her2/neu expression lev-
el, maintenance of Her2/neu-status and increase of ER expression level in
local metastases compared with primary tumour of breast cancer in the
cases with equivocal (2+) Her2/neu expression level in the primary tumour.
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Background & Objectives: Male breast cancer (MBC) is a rare con-
dition representing the 0.5-1% of all breast cancer cases. In contrast
to female breast cancer (FBC), relatively little is known about MBC.
Most MBCs are luminal A or B types, whereas basal-like and HER2
enriched types are rare. This distribution is clearly different com-
pared to FBC, pointing to possible important differences in carcino-
genesis. Increasing data deal with the role of the androgen receptor
(AR) as a marker of prognosis in FBC, with contrasting results. Since
the androgen – AR signalling exerts actions on key events during
prostate carcinogenesis, the aim of the present study was to evaluate
the role of AR in MBC.
Methods: 23 males with a diagnosis of invasive breast cancer were
selected. Clinico-pathological data were collected. AR expression
was measured by immunohistochemistry (SP107, Ventana Medical
Systems; Ventana BenchMark AutoStainer). Pathological variables
were compared by Spearman’s rank correlation coefficient.
Moreover, the Kaplan–Meier method and log-rank test were used
to explore the impact of AR expression on disease free survival
(DFS).
Results: 16 out of 23 patients (70%) displayed and increase of AR ex-
pression with the increase of Progesterone Receptor (PgR) expression
(rho = 0,484; p = 0,019). Instead, 7 out of 23 patients (30%) with low
levels of PgR displayed high levels of AR with a potential advantage in
terms of DFS (p=0,081).
Conclusion: These preliminary data suggest a possible prognostic role of
AR inMBC. Forthcoming molecular analysis will shed light to unknown
underlying mechanisms.
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Background & Objectives: The course of the breast cancer (BC)
depends on the differentiation of the tumour, immunophenotype of
the neoplastic cells and the qualitative and quantitative characteris-
tics of the tumour microenvironment. Moreover, the expressed sec-
ondary changes significantly influence on the progression of the
malignant process in the mammory gland. We present the case of
the invasive breast cancer (non-specific type) of the right breast in a
64-year-old woman with the features of the expressed rare type of
metaplasia.
Methods: Morphogenesis and immunophenotype of the tumour were
studied by using the histological (H&E) and immunohistochemical
(CKpan, Er, Pr, PRL, Her2neu, Ki-67, EGFR, MPO, GPA, CD3,
CD79, CD68, OPN and OSN) methods.
Results: The high-grade invasive cancer of non-specific type with
the expressed cartilaginous and osseous metaplasia was diagnosed.
Immunohistochemical study revealed the strong expression for
CKpan, OPN, OSN, PRL, moderate-EGFR, weak-Er, negative-Pr
and Her2neu in the cancer tissue; Ki-67 expression was found in
7% of tumour cells. In the areas of osseous and cartilaginous tis-
sue, the accumulation of single CD3, CD79α vs CD68 positive
cells with MPO and GPA positive cells was revealed which con-
firms the formation of red bone marrow in the centre of
metaplasia.
Conclusion: This clinical observation presents the case of the
breast cancer, where the immunophenotype of cancer cells is the
indicator of the possible osteo/chondrogenesis with the formation
of bone marrow. Timely determination of the expression peculiar-
ities of immunohistochemical markers in cartilaginous and osseous
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metaplasia makes it possible to predict the course of the oncolog-
ical disease and its metastasis.
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Background & Objectives: Adenoid cystic carcinoma (ACC) is a rare
but distinct breast neoplasm resembling its counterpart in other organs. It is
architecturally heterogeneous and composed of a dual cell population,
expressing epithelial and myoepithelial markers. Nevertheless, there is
some controversy in the literature regarding its immunohistochemical pro-
file. The aim of this study was to characterise the clinical, histological and
immunohistochemical features of ACC cases diagnosed in our Institution.
Methods: A retrospective analysis of patients with ACC of the breast in
our Institution was carried out. Twelve cases were included (1987-2018).
Histological pattern and Nottingham Histological Grade (NG) were eval-
uated. Immunohistochemistry with hormonal receptors (estrogen-ER and
progesterone-PR), human epidermal growth factor receptor type 2
(HER2), p63, calponin, vimentin, S100, smooth muscle actin (SMA),
CK7, CAM5.2, CK5/6, CD117 and CK14 was performed for each case.
Results: Mean tumour size was 2,2cm. NG was 1(n=7), 2(n=3) and
3(n=1). Six cases were predominantly tubular/cribriform and six had
solid/basaloid areas. 75% were triple-negative. All cases stained for
CK7 and vimentin and eleven for CD117 and p63, each. Remaining
markers stained variably. In predominantly tubular/cribriform tumours
CK7, CD117, p63 and vimentin clearly identified two different cell pop-
ulations. In solid tumours there was more epithelial-myoepithelial stain-
ing overlap with these markers. NG3 case was the only with nodal and
distant metastasis.
Conclusion:ACC has good prognosis and characteristic histological and
immunohistochemical features. Nevertheless, in tumours with predomi-
nantly solid/less differentiated areas there is more histological and immu-
nohistochemical heterogeneity, which makes the differential diagnosis
with other basaloid salivary gland-like carcinomas of the breast more
challenging.
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Background & Objectives: Male breast carcinoma is still inadequately
characterised and data regarding the impact of different prognostic pa-
rameters are limited due to the small number of cases compared to female
counterpart. The objective of this study is to evaluate clinical-pathological
parameters in correlation with OS in male breast carcinoma.
Methods: All men diagnosed with invasive breast carcinoma in 6 inter-
national Institutions (1999- 2015) were identified by searching laboratory
databases. Parameters analysed were the followings: age, tumour size,
histological tumour type and grade, molecular biomarkers (ER, PR, ki-
67, HER2), AR status, treatment and length of OS (months).
Results: 217 cases, with a mean age of 62y (range: 18- 85), right breast
localization (52.53%), NST histological type (86.18%), G2 histological
grade (55.4%), T2 (54.41%), N+ (65.89%) and Luminal A molecular
subtype (85.29%) were identified. 5-year OS was 67.2% and 10-year
OS was 48.5%. OS was 92.7% at 5 years and 73.8% at 10 years (in
axillary lymph node negative cases) while OS was 59.7% at 5 year and
41.3% at 10 years in axillary positive male cancers (p=0.003).
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Background & Objectives: Breast cancer (BC) in adolescents and
young adults (AYAs; 15-49 years) is associated with aggressive tumour
features. We aimed to investigate tumour cell proliferation in AYAs.
Methods: The proliferation marker Ki67 was analysed by immuno-
histochemistry on FFPE TMA-slides from two population based co-
horts: One AYA series (n=355) and one series of patients aged 50-69
(n=546). mRNA data from METABRIC and TCGA (n=2283) was
used to investigate gene expression signatures reflecting tumour
proliferation.
Results: The AYAs demonstrated higher Ki67 levels compared to BC
patients ≥ 50 years (median Ki67 10.4% and 7.0%, respectively;
P<0.0005). Higher Ki67 levels were found among AYAs <40 years com-
pared to those 40-49 years (median Ki67: 16.0% and 9.0%, respectively;
P=0.009). High levels of Ki67 among AYAs were associated with high
histologic grade, ER and PR negativity, larger tumour diameter, and
shorter survival (all P<0.0005). When adjusting for tumour size, histo-
logic grade and lymph node status, Ki67 maintained independent prog-
nostic impact, also among ER positive AYA tumours. Higher mRNA
proliferation scores in the young, and associations between high scores
and shorter survival, validated our results (all P<0.0005).
Conclusion: BC of the young demonstrate higher tumour cell prolifera-
tion compared to older patients, and higher proliferation associate with
aggressive tumour features and reduced survival among AYA patients.
This might contribute to the more aggressive breast cancers observed in
the young.
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